OBJECTIVE: To investigate the risk factors for, and the incidence of, structural abnormalities on brain imaging in allogeneic haematopoietic stem cell transplant (HSCT) patients, and correlate these findings with survival. METHODS: We retrospectively reviewed all brain computed tomography (CT) and/or magnetic resonance imaging (MRI) studies obtained during the first post-HSCT year from 2004 thru 2007 in allogeneic HSCT recipients. RESULTS: A total of 128 patients had brain imaging in the first post-HSCT year. Forty one of these 128 patients (32 %) had structural abnormalities on brain imaging: cerebrovascular complications (n = 10), central nervous system (CNS) infection (n = 9), subdural fluid collection (n = 6), CNS recurrence of haematological malignancy (n = 11), and drug toxicity abnormalities (n = 5). The only significant risk factor for structural imaging abnormality was younger patient age (P = 0.01). MRI was significantly more likely than CT to provide specific imaging diagnosis of cerebral lesions (P = 0.001). HSCT patients with cerebrovascular complications have poor survival (P < 0.05). However, overall survival was not significantly worse for the 41 patients with the structural imaging abnormalities as compared to the 87 patients who had brain imaging but no structural abnormalities. CONCLUSIONS: There was no survival difference in patients whose brain imaging was normal or abnormal. However, there was poor outcome in patients with cerebrovascular complications after HSCT. KEY POINTS : • Brain imaging frequently demonstrates neurological complications following haematopoietic stem cell transplantation. • Younger HSCT patients are more likely to exhibit abnormal brain imaging findings. • HSCT recipients with cerebrovascular complications have the worst survival. • However brain imaging results are weak indicators of overall survival after HSCT.
OBJECTIVE: To investigate the risk factors for, and the incidence of, structural abnormalities on brain imaging in allogeneic haematopoietic stem cell transplant (HSCT) patients, and correlate these findings with survival. METHODS: We retrospectively reviewed all brain computed tomography (CT) and/or magnetic resonance imaging (MRI) studies obtained during the first post-HSCT year from 2004 thru 2007 in allogeneic HSCT recipients. RESULTS: A total of 128 patients had brain imaging in the first post-HSCT year. Forty one of these 128 patients (32 %) had structural abnormalities on brain imaging: cerebrovascular complications (n = 10), central nervous system (CNS) infection (n = 9), subdural fluid collection (n = 6), CNS recurrence of haematological malignancy (n = 11), and drug toxicity abnormalities (n = 5). The only significant risk factor for structural imaging abnormality was younger patient age (P = 0.01). MRI was significantly more likely than CT to provide specific imaging diagnosis of cerebral lesions (P = 0.001). HSCT patients with cerebrovascular complications have poor survival (P < 0.05). However, overall survival was not significantly worse for the 41 patients with the structural imaging abnormalities as compared to the 87 patients who had brain imaging but no structural abnormalities. CONCLUSIONS: There was no survival difference in patients whose brain imaging was normal or abnormal. However, there was poor outcome in patients with cerebrovascular complications after HSCT. KEY POINTS : • Brain imaging frequently demonstrates neurological complications following haematopoietic stem cell transplantation. • Younger HSCT patients are more likely to exhibit abnormal brain imaging findings. • HSCT recipients with cerebrovascular complications have the worst survival. • However brain imaging results are weak indicators of overall survival after HSCT.
Authors: M S Brown; J H Simon; S M Stemmer; J C Stears; A Scherzinger; P J Cagnoni; R B Jones Journal: AJNR Am J Neuroradiol Date: 1995 Nov-Dec Impact factor: 3.825
Authors: L F Bleggi-Torres; B C de Medeiros; B Werner; J Z Neto; G Loddo; R Pasquini; C R de Medeiros Journal: Bone Marrow Transplant Date: 2000-02 Impact factor: 5.483
Authors: D Uckan; M Cetin; I Yigitkanli; I Tezcan; M Tuncer; D Karasimav; K K Oguz; M Topçu Journal: Bone Marrow Transplant Date: 2005-01 Impact factor: 5.483
Authors: C Weber; J Schaper; D Tibussek; O Adams; C R Mackenzie; D Dilloo; R Meisel; U Göbel; H-J Laws Journal: Bone Marrow Transplant Date: 2007-11-05 Impact factor: 5.483
Authors: Y Miaux; P Ribaud; M Williams; A Guermazi; E Gluckman; C Brocheriou; M Laval-Jeantet Journal: AJNR Am J Neuroradiol Date: 1995-03 Impact factor: 3.825
Authors: J Wojnar; S Giebel; A Holowiecka-Goral; M Markiewicz; I Wylezol; M Kopera; M Krawczyk-Kulis; J Holowiecki Journal: Transplant Proc Date: 2007-12 Impact factor: 1.066
Authors: Elena Marín-Díez; Marta Drake-Pérez; Natalia Valle-San Román; Víctor Manuel Mora Cuesta; Miguel Ángel Hernández-Hernández; Enrique Marco de Lucas Journal: Acta Radiol Open Date: 2021-10-03